SCHEDULE 13G 0001281446 XXXXXXXX LIVE Ordinary shares, nominal value 0.01 Euro per share 05/05/2025 0001756594 Inventiva S.A. F5R343107 50 rue de Dijon Daix I0 21121 Rule 13d-1(c) Great Point Partners, LLC DE 0.00 10576827.00 0.00 10576827.00 10576827.00 N 7.42 IA OO Dr. Jeffrey R. Jay, M.D. X1 0.00 10576827.00 0.00 10576827.00 10576827.00 N 7.42 HC IN Ms. Lillian Nordahl X1 0.00 10576827.00 0.00 10576827.00 10576827.00 N 7.42 HC IN Inventiva S.A. 50 rue de Dijon, 21121 Daix France Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated June 20, 2025, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830 Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States. Y 10,576,827 7.42% 0 10,576,827 0 10,576,827 The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 139,151,274 shares outstanding, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission (the "SEC") on May 5, 2025 and 3,333,332 shares of the Common Stock issuable upon exercise of warrants held by the reporting persons. Biomedical Value Fund, L.P. ("BVF") is the record holder of 4,853,356 shares of Common Stock (the "BVF Shares"). Such shares constitute 3.41% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BVF is the record holder of warrants to purchase an additional 2,166,666 shares of Common Stock (the "BVF Warrants"). All shares underlying such warrants are exercisable, which constitutes 1.52% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record holder of 2,390,139 shares of Common Stock (the "BOVF Shares"). Such shares constitute 1.68% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BOVF is the record holder of warrants to purchase an additional 1,166,666 shares of Common Stock (the "BOVF Warrants"). All shares underlying such warrants are exercisable, which constitutes 0.82% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. Notwithstanding the above, Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interests. In addition to an aggregate of 7,407,406 shares of the Issuer's common stock (the "Common Stock") in the aggregate held outright, the reporting persons hold in the aggregate warrants to purchase 3,333,332 shares of Common Stock. All shares underlying such warrants are beneficially owned by the reporting persons. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. 1. Great Point Partners, LLC (a) Amount beneficially owned: 10,576,827 (b) Percent of class: 7.42% (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 10,576,827 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 10,576,827 2. Dr. Jeffrey R. Jay, M.D. (a) Amount beneficially owned: 10,576,827 (b) Percent of class: 7.42% (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 10,576,827 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 10,576,827 3. Ms. Lillian Nordahl (a) Amount beneficially owned: 10,576,827 (b) Percent of class: 7.42% (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 10,576,827 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 10,576,827 Based on a total of 139,151,274 shares outstanding, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission (the "SEC") on May 5, 2025 and 3,333,332 shares of the Common Stock issuable upon exercise of warrants held by the reporting persons. Y N See Item 4. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: June 20, 2025 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D 06/20/2025 Dr. Jeffrey R. Jay, M.D. /s/ Dr. Jeffrey R. Jay, M.D 06/20/2025 Ms. Lillian Nordahl /s/ Ms. Lillian Nordahl 06/20/2025